$954 Million is the total value of Camber Capital Management LP's 34 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 87.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDcall | $75,560,000 | +863.8% | 2,000,000 | +900.0% | 7.92% | +882.6% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDadr | $75,560,000 | +157.0% | 2,000,000 | +166.7% | 7.92% | +161.9% |
| MYL | Buy | MYLAN INC | $72,523,000 | +29.8% | 1,900,000 | +5.6% | 7.60% | +32.3% |
| V107SC | Buy | WELLPOINT INC | $71,068,000 | +8.5% | 850,000 | +6.2% | 7.45% | +10.6% |
| HOLX | Buy | HOLOGIC INC | $46,462,000 | +20.4% | 2,250,000 | +12.5% | 4.87% | +22.7% |
| MNKKQ | New | MALLINCKRODT PUB LTD CO | $33,067,000 | – | 750,000 | +100.0% | 3.47% | – |
| HCA | New | HCA HOLDINGS INC | $32,062,000 | – | 750,000 | +100.0% | 3.36% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $25,965,000 | – | 500,000 | +100.0% | 2.72% | – |
| A | New | AGILENT TECHNOLOGIES INC | $25,625,000 | – | 500,000 | +100.0% | 2.69% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $23,615,000 | – | 500,000 | +100.0% | 2.48% | – |
| NVAX | Buy | NOVAVAX INC | $14,887,000 | +126.1% | 4,711,009 | +46.7% | 1.56% | +130.4% |
| PLX | Buy | PROTALIX BIOTHERAPEUTICS INC | $8,109,000 | +10.1% | 1,790,000 | +19.3% | 0.85% | +12.1% |
| BIOL | New | BIOLASE INC | $5,134,000 | – | 2,688,172 | +100.0% | 0.54% | – |
| UAM | Buy | UNIVERSAL AMERN CORP NEW | $5,110,000 | +10.5% | 670,600 | +28.9% | 0.54% | +12.6% |
| XNPT | New | XENOPORT INC | $4,600,000 | – | 809,943 | +100.0% | 0.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.